Silence Therapeutics plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Silence Therapeutics plc
It is time for In Vivo's 13th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
With a candidate COVID-19 therapy in clinical development, the UK’s Synairgen has raised $101m on the UK’s AIM to support clinical studies and manufacturing plans.
The UK's Silence Therapeutics is moving its candidate products into early clinical studies in cardiovascular diseases and improving its visibility with a NASDAQ listing.
With recently secured platform technology and various programs now entering clinical trials, South Korean RNAi therapeutics company OliX Pharmaceuticals is hoping to reach multiple licensing deals by next year.
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Atugen AG
- Intradigm Corporation
- SR Pharma plc